<i>Drosophila</i> as a Model of Unconventional Translation in Spinocerebellar Ataxia Type 3

RNA toxicity contributes to diseases caused by anomalous nucleotide repeat expansions. Recent work demonstrated RNA-based toxicity from repeat-associated, non-AUG-initiated translation (RAN translation). RAN translation occurs around long nucleotide repeats that form hairpin loops, allowing for tran...

Full description

Bibliographic Details
Published in:	Cells
Main Authors:	Sean L. Johnson, Matthew V. Prifti, Alyson Sujkowski, Kozeta Libohova, Jessica R. Blount, Luke Hong, Wei-Ling Tsou, Sokol V. Todi
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Subjects:	ataxin-3 Gal4-UAS glia Machado–Joseph disease neuron neurodegeneration
Online Access:	https://www.mdpi.com/2073-4409/11/7/1223

Similar Items

Nystagmus may be the first neurological sign in early stages of spinocerebellar ataxia type 3
by: Maria Thereza Drumond Gama, et al.
Published: (2021-01-01)

Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation
by: Sean L Johnson, et al.
Published: (2020-09-01)

Regional and age-dependent changes in ubiquitination in cellular and mouse models of spinocerebellar ataxia type 3
by: Haiyang Luo, et al.
Published: (2023-04-01)

Polyglutamine length-dependent toxicity from α1ACT in Drosophila models of spinocerebellar ataxia type 6
by: Wei-Ling Tsou, et al.
Published: (2016-12-01)

A Difficult Case to Diagnose: Machado-Joseph Disease/Spinocerebellar Ataxia Type III
by: Muhammad Sohail Ajmal Ghoauri, et al.
Published: (2023-12-01)

Differential toxicity of ataxin-3 isoforms in Drosophila models of Spinocerebellar Ataxia Type 3
by: Sean L. Johnson, et al.
Published: (2019-12-01)

Itajaí, Santa Catarina – Azorean ancestry and spinocerebellar ataxia type 3
by: Hélio A. G. Teive, et al.

Ubiquitin-binding site 1 of pathogenic ataxin-3 regulates its toxicity in Drosophila models of Spinocerebellar Ataxia Type 3
by: Matthew V. Prifti, et al.
Published: (2023-01-01)

Clinical relevance of "bulging eyes" for the differential diagnosis of spinocerebellar ataxias
by: Adriana Moro, et al.
Published: (2013-07-01)

Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo
by: Maxinne Watchon, et al.
Published: (2021-08-01)

Machado-Joseph disease in Brazil: from the first descriptions to the emergence as the most common spinocerebellar ataxia
by: José Luiz Pedroso, et al.
Published: (2012-08-01)

Assessment of Bone Mineral Density of Patients with Spinocerebellar Ataxia Type 3
by: Aline MS Farias, et al.
Published: (2019-01-01)

Ataxin-3, The Spinocerebellar Ataxia Type 3 Neurodegenerative Disorder Protein, Affects Mast Cell Functions
by: Anna S. Sowa, et al.
Published: (2022-04-01)

Recurrent divergence-insufficiency esotropia in Machado-Joseph disease (spinocerebellar ataxia type 3)
by: Jeannette Y. Stallworth, et al.
Published: (2022-12-01)

Spinocerebellar ataxia type 3: subphenotypes in a cohort of brazilian patients
by: Adriana Moro, et al.
Published: (2014-09-01)

RNAi or overexpression: Alternative therapies for Spinocerebellar Ataxia Type 1
by: Megan S. Keiser, et al.
Published: (2013-08-01)

Pathogenesis of SCA3 and implications for other polyglutamine diseases
by: Hayley S. McLoughlin, et al.
Published: (2020-02-01)

Ataxin-3 and its E3 partners: Implications for Machado-Joseph disease
by: Thomas M Durcan, et al.
Published: (2013-05-01)

Modest Reduction in CAG Repeat Length Rescues Motor Deficits but Not Purkinje Cell Pathology and Gliosis in Spinocerebellar Ataxia Type 1 Mice
by: Stephen Gilliat, et al.
Published: (2023-03-01)

Research progress of miRNA and siRNA in spinocerebellar ataxia type 3
by: Feng-zhen HUANG, et al.
Published: (2013-08-01)

A Novel Calpain Inhibitor Compound Has Protective Effects on a Zebrafish Model of Spinocerebellar Ataxia Type 3
by: Katherine J. Robinson, et al.
Published: (2021-09-01)

Pathogenetic Mechanisms Underlying Spinocerebellar Ataxia Type 3 Are Altered in Primary Oligodendrocyte Culture
by: Kristen H. Schuster, et al.
Published: (2022-08-01)

Sleep Alterations in a Mouse Model of Spinocerebellar Ataxia Type 3
by: Maria-Efstratia Tsimpanouli, et al.
Published: (2022-10-01)

An Optimal Ubiquitin-Proteasome Pathway in the Nervous System: The Role of Deubiquitinating Enzymes
by: Gorica eRistic, et al.
Published: (2014-08-01)

Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model
by: Ajayi Abiodun, et al.
Published: (2012-07-01)

Progressive degeneration in a new Drosophila model of spinocerebellar ataxia type 7
by: Alyson Sujkowski, et al.
Published: (2024-06-01)

The Natural History of Spinocerebellar Ataxia Type 3 in Mainland China: A 2-Year Cohort Study
by: Yun Peng, et al.
Published: (2022-07-01)

Enhanced Age-Dependent Motor Impairment in Males of <i>Drosophila melanogaster</i> Modeling Spinocerebellar Ataxia Type 1 Is Linked to Dysregulation of a Matrix Metalloproteinase
by: Emma M. Palmer, et al.
Published: (2024-10-01)

A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats
by: Jana Boy, et al.
Published: (2010-02-01)

On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3
by: Sousa André, et al.
Published: (2023-02-01)

Long-read sequencing identifies ATXN3 repeat expansions, and transcriptomics reveals disease progression biomarkers and druggable targets for spinocerebellar ataxia type 3
by: Chang Liu, et al.
Published: (2025-09-01)

Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches
by: Luis C. Velázquez-Pérez, et al.
Published: (2017-09-01)

Flow cytometry allows rapid detection of protein aggregates in cellular and zebrafish models of spinocerebellar ataxia 3
by: Katherine J. Robinson, et al.
Published: (2021-10-01)

Effect of speech therapy on quality of life in patients with spinocerebelar ataxia type 3
by: Giovana Diaféria, et al.
Published: (2022-10-01)

Gene Suppression Therapies in Hereditary Cerebellar Ataxias: A Systematic Review of Animal Studies
by: Carolina Santos, et al.
Published: (2023-03-01)

Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease
by: Mafalda Raposo, et al.
Published: (2024-04-01)

Spermidine treatment: induction of autophagy but also apoptosis?
by: Maxinne Watchon, et al.
Published: (2024-03-01)

The Josephin domain (JD) containing proteins are predicted to bind to the same interactors: Implications for spinocerebellar ataxia type 3 (SCA3) studies using Drosophila melanogaster mutants
by: Rita Sousa e Silva, et al.
Published: (2023-03-01)

A família Drew de Walworth: um século após a avaliação inicial finalmente o diagnóstico doença de Machado-Joseph The Drew family of Walworth: one century from the first evaluation until the final diagnosis, Machado-Joseph disease
by: Hélio A. Ghizoni Teive, et al.
Published: (2004-03-01)

Insights into dentatorubral-pallidoluysian atrophy from a new Drosophila model of disease
by: Matthew V. Prifti, et al.
Published: (2025-04-01)